Forty Seven Inc., of Menlo Park, Calif., said it inked a deal with Darmstadt, Germany-based Merck KGaA to conduct a phase Ib trial combining CD47-targeting candidate Hu5F9-G4 with PD-1/PD-L1-targeting Bavencio (avelumab) in patients with ovarian cancer. Read More
Xortx Pharma Corp., of Calgary, Alberta, said it completed a reverse merger with Apac Resources Inc., with the resulting company, Xortx Therapeutics Inc., to focus on developing therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid, including type 2 diabetic nephropathy, cardiovascular disease and diabetes. Read More
Braeburn Pharmaceuticals Inc., of Princeton, N.J., said it completed a $110 million mezzanine round of financing led by Wellington Capital Management. Read More
HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million). Read More
SAN FRANCISCO – A shifting regulatory climate and an increasing push for innovation combined with a staggering amount of capital is expected to significantly increase the rate of cross-border dealmaking between China firms and U.S.-based and multinational companies, experts predicted during the Chinese American Biopharmaceutical Society meeting Wednesday. Read More
SAN FRANCISCO – Sophie Kornowski-Bonnet wasn't on the same stage that Glaxosmithkline plc CEO Emma Walmsley commanded a day earlier at the 36th Annual J.P. Morgan Healthcare Conference, but the standing-room-only crowd was equally eager to hear the thoughts of the Roche Holding AG official on the future of biopharma development and on her pioneering role as one of the industry's top female business development chiefs. Read More
SAN FRANCISCO – Our immune system is in a constant state of flux not only adapting to disease perturbations but also retaining a "memory" of the invading pathogens so it is ready to instantly recognize and produce a response to them in the future. What if we could interpret this immune memory blueprint? It would provide a fascinating window into a person's health history. Read More
Instead of a thumbs up from the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee Wednesday, Lipocine Inc.'s Tlando was downed by safety concerns. While six committee members supported approval of the oral testosterone undecanoate capsule as a testosterone replacement therapy (TRT) for men with primary hypogonadism and hypogonadotropic hypogonadism, 13 panelists said the overall benefit/risk profile was not acceptable. Read More
